Business

According to North Carolina-based Cornerstone Therapeutics, Chiesi Farmaceutici has offered to purchase shares of Cornerstone’s common stock for between $6.40 and $6.70 per share, to take the company private. Chiesi already owns approximately 60% of… Read more . . .

CRO Quintiles says that it has filed a registration statement with the US. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of an undisclosed number of shares of common stock. The company… Read more . . .

Discovery Laboratories says that Deerfield Management Company will provide the company up to $30 million in the form of a secured loan facility. Discovery Labs will use the money for development and commercialization of its… Read more . . .

MeadWestvaco has announced a $7.5 million expansion of its pharmaceutical manufacturing Centre of Excellence in Hemer, Germany, an expansion the company attributes largely to growth in the preservative-free nasal product market. According to the company,… Read more . . .

The US Patent and Trade Office (USPTO) has granted Mystic Pharmaceuticals US Patent No. 8,377,009, according to the company. The patent, titled “Intranasal Cartridge Devices,” covers technology for a delivery system based on Mystic’s unit… Read more . . .

Allergan will acquire Levadex inhaled dihydroergotamine developer MAP Pharmaceuticals for $25 per share. The two companies entered into an agreement to co-promote Levadex in January 2011, and MAP submitted an NDA for the product later… Read more . . .

Catalent Pharma Solutions has announced that it will invest $20 million to enhance pMDI clinical and commercial supply capabilities, along with other enhancements, at its Inhalation Center of Excellence in Research Triangle Park (RTP), North… Read more . . .

The Bluetooth Special Interest Group (SIG) has named Asthmapolis a finalist in the “Breakthrough Products” category for the Bluetooth Breakthrough Awards. The FDA granted 510(k) clearance to the Asthmapolis inhaler sensor system and mobile app… Read more . . .